摘要：目的 探讨MUC1在子宫内膜癌组织的表达及意义.方法 免疫组化SP法检测20例增生期子宫内膜、20例不典型增生子宫内膜以及58例子宫内膜癌组织中粘蛋白MUC1的表达及其与临床病理特征的关系.结果 子宫内膜癌组中和不典型增生组中MUC1阳性细胞率分别为46.6%(27/58)和35.0%(7/20),明显高于增生期子宫内膜组(5%,4/20),二者比较差异有统计学意义(P＜0.05);在FIGOⅡ期、Ⅲ期的阳性表达率分别为57.9%(11/19)和87.5%(7/8),明显高于FIGO Ⅰ期(29.0%,9/31),二者比较差异有统计学意义(P＜0.05);在肌层浸润深度≤1/2者的阳性表达率(25.7%,9/35)明显低于浸润深度＞1/2者(78.3%,18/23),二者比较差异有统计学意义(P＜0.05);无淋巴结转移者的阳性表达率(40.4%,21/52)明显低于有淋巴结转移者(100%,6/6),二者比较差异有统计学意义(P＜0.05),而与组织分化级别无关(P＞0.05).结论 MUC1可能参与了子宫内膜癌的发生发展及浸润转移,与子宫内膜癌的恶性程度高有关. Abstract： Objective To investigate the MUC1 expression in endometrial carcinoma and its clinical significance. Methods Twenty specimen of normal endometrial in proliferative phase, twenty specimen of atypical hyperplasia and fifty eight specimen of endometrial carcinoma were studied. Immunohistochemistry was used to study the expression of MUC1. Results The positive rates of MUC1 in endometrial carcinoma group and atypical hyperplasia group were 46.6% (27/58)and 35.0% (7/20), significantly higher than that in normal proliferative endometrial group (5% ,4/20). In endometrial carcinoma group the positive rate of MUC1 in FIGO stage Ⅱ and Ⅲ were respectively 57.9% (11/19) and 87.5% (7/8), significantly higher than that in stage Ⅰ (38.7% ,12/31), P ＜0.05 ,the positive rate of MUC1 in cases of deep myometrial invasion (78.3% , 18/23) was significantly higher that in superficial myometrial invasion (25.7% ,9/35), the positive rate of MUC1 in cases of positive lymph mestst

注：因版权方要求，不能公开全文，如需全文，请咨询杂志社